{
    "clinical_study": {
        "@rank": "48440", 
        "arm_group": {
            "arm_group_label": "Liraglutide", 
            "description": "administration of liraglutide at 1.2 mg/daily"
        }, 
        "biospec_descr": {
            "textblock": "serum and plasma samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Incretin-based therapies have shown significant effects beyond those on glucose metabolism.\n      We aim in the present study to evaluate the effects of liraglutide on several\n      cardio-metabolic risk markers."
        }, 
        "brief_title": "Liraglutide and Cardio-Metabolic Risk Markers", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type-2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "In details, we will evaluate the effects of liraglutide on carotid-intima media thickness,\n      oxidative stress, ghrelin, heat shock proteins and lipoproteins."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - patients with a diagnosis of type-2 diabetes\n\n        Exclusion Criteria:\n\n        - severe hepatic or renal diseases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "adult subjects with type-2 diabetes"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715428", 
            "org_study_id": "LIRAGLUTIDE UNIPA"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "diabetes, cardiovascular risk", 
        "lastchanged_date": "October 25, 2012", 
        "location": {
            "contact": {
                "email": "manfredi.rizzo@unipa.it", 
                "last_name": "Manfredi Rizzo, MD, PhD", 
                "phone": "+390916552945"
            }, 
            "facility": {
                "address": {
                    "city": "Palermo", 
                    "country": "Italy", 
                    "zip": "90127"
                }, 
                "name": "University Hospital of Palermo"
            }, 
            "investigator": {
                "last_name": "Manfredi Rizzo, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_groups": "1", 
        "official_title": "Effects of Liraglutide on Cardio-Metabolic Risk Markers", 
        "overall_contact": {
            "email": "manfredi.rizzo@unipa.it", 
            "last_name": "Manfredi Rizzo, MD, PhD", 
            "phone": "+390916552945"
        }, 
        "overall_official": {
            "affiliation": "University of Palermo, Italy", 
            "last_name": "Giuseppe Montalto, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "carotid intima-media thickness will be assessed by doppler ultrasonography", 
            "measure": "carotid intima-media thickness", 
            "safety_issue": "No", 
            "time_frame": "every four months for a total period of 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715428"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Palermo", 
            "investigator_full_name": "Manfredi Rizzo", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins will be measured by high-quality technologies", 
            "measure": "changes in oxidative stress, ghrelin, atherogenic lipoproteins, heat shock proteins", 
            "safety_issue": "No", 
            "time_frame": "after 2 months of therapy"
        }, 
        "source": "University of Palermo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Palermo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2012"
    }
}